Multiple studies have found that people age 65 and older are underrepresented in both cancer registration trials and the National Cancer Institute’s National Clinical Trials Network (NCTN) clinical trials, with only modest improvement over time.
Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer.
Not only did lymphadenectomy yield no improvement in overall survival, but patients who underwent the procedure faced greater morbidity in terms of serious postoperative complications and greater early mortality following surgery.
Although patients have benefited from the expansion of options, questions have arisen about how to select optimal treatment, such as whether to recommend lymph node dissection or immunotherapy compared with targeted therapy.
Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.
In 2015, ASCO and AACI led a multi-stakeholder survey to identify and prioritize the most burdensome regulatory and/or administrative aspects of clinical trials: clinical trial contracting, clinical trial coverage analyses and budgeting, and training and regulatory requirements.
With appropriate oversight by regulatory authorities, professional organizations such as ASCO, and patient and clinician education programs, we will see the potential for considerable cost savings and increased access and equity of cancer care through the use of biosimilars.
Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who were given chemotherapy with cediranib followed by maintenance therapy with cediranib in the ICON6 trial.